Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. A substantial proportion (30–40% per year) of pa-tients with mild cognitive impairment (MCI) progress to AD [2], making early and accurate prognostication essential for timely intervention, trial enrichment, and resource allocation. This paper presents a comprehensive review of a re-cent longitudinal MRI-based study by Aghajanian et al. [1], which integrates three-dimensional (3D) convolutional neural networks (CNNs), time-aware long short-term memory (T-LSTM) networks with attention mechanisms, and radiomics features to predict MCI-to-AD conversion using structural MRI. The cohort comprises 228 ADNI MCI participants with at least three T1-weighted MRI scans over an 18-month window (684 scans in total) [1]. A 3D Res-Net-18 backbone [9] extracts volumetric features, fed into a T-LSTM incorporating inter-scan intervals and attention mechanisms [10]. The best longitudinal model achieves a concordance index (c-index) of 0.90, with time-specific AUCs of 0.96, 0.94, and 0.89 for 2-, 3-, and 5-year conversion prediction, respectively, and an approximate 11-fold hazard ratio between high- and low-risk groups [1]. This review analyzes the methodology, highlights its strengths and weaknesses, and discusses key implications for clinical translation.

Key findings

Why it matters

A reviewed longitudinal MRI study using 3D CNNs, T-LSTM networks, and radiomics predicted MCI-to-AD conversion with a c-index of 0.90 and time-specific AUCs of 0.96, 0.94, and 0.89 for 2-, 3-, and 5-year prediction. This is a prediction and prognostication tool, not a treatment, cure, or prevention.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 35 of the 89 points it could be judged on, which is 39 of 100. Total 39 of 100.35 of the 89 points we could judge = 39 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, senior author's track record and institution's track record, so those were left out: it earned 35 of the 89 points we could judge it on, which is 39 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research))
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Prof. Rahul Patidar holds only 6 work(s), too few to judge a track record — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 35 / 89 Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 35 of the 89 points we could judge it on is 39 out of 100.
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Pawar, D., Boaddh, J., & Patidar, P. R. (2026). Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18620943

Vancouver

Pawar D, Boaddh J, Patidar PR. Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.18620943.

BibTeX

@article{pawar2026-4f4d861f,
  author  = {Pawar, Diksha and Boaddh, Jayshree and Patidar, Prof. Rahul},
  title   = {{Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer's Disease Progression}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.18620943},
  url     = {https://doi.org/10.5281/zenodo.18620943}
}

Related studies in Brain scans and imaging

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →